Fundraising FoxACORN BIOVENTURES — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.
BiotechHealthtechGeneva
Roger Mills(Executive Officer, Director)inMikhail Kalinichev(Executive Officer)inJean-Philippe Rocher(Executive Officer)inRobert Lutjens(Executive Officer)inTimothy Dyer(Executive Officer, Director)Vincent Lawton(Director)
Board seatIsaac Manke· per SEC Form D · $5.9M raise · filed Dec 2021
Co-investorsNew Enterprise Associates (NEA)Sofinnova PartnersSR One Capital Management
Eliem Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies targeting immune-mediated diseases, with budoprutug, an anti-CD19 antibody designed to deplete B cells in conditions including primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL antibody for IgA nephropathy and related B-cell mediated diseases.
BiotechWilmington, US
Valerie Morisset(Executive Officer)inErin Lavelle(Executive Officer)inRobert Azelby(Executive Officer, Director)James Bucher(Executive Officer)Leone Patterson(Director)
BoardAdam Rosenberg(Director)
Co-investorsManta Ray VenturesAccess BiotechnologyIntermediate Capital GroupLifeArc VenturesRA Capital
Conflu-X Technology manufactures thermal management products including cold plates, intercoolers, and liquid cooling solutions for automotive, aviation, data center, defense, and industrial applications.
Advanced ManufacturingData & InfrastructureHardware
Co-investorsAM VenturesBreakthrough Victoria
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.